OOIR: Observatory of International Research

Papers

(The median citation count of Cancer and Metastasis Reviews is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	172
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities	166
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression	134
The functions and modifications of tRNA-derived small RNAs in cancer biology	96
Clonal tracking in cancer and metastasis	88
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective	73
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	69
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms	67
The role of microbiome in pancreatic cancer	62
Obesity and cancer	57
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	47
Regulation of dormancy during tumor dissemination: the role of the ECM	47
CAR T-cell therapy to treat multiple myeloma: current state and future directions	46
Targeting lipid metabolism in cancer: neuroblastoma	46
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor	46
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations	46
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer	44
Cell-cell interactions mediating primary and metastatic breast cancer dormancy	43
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond	41
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review	40
Correction to: Cutting the edge between cancerogenesis and organogenesis of the pancreatic endocrine lineage allocation—comprehensive review of the genes Synaptotagmin 13 and 533041C22 Rik in epitheli	39
p73 isoforms meet evolution of metastasis	36
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	36
Preface	35
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives	35

Biography—Mathieu Boissan, Pharm.D., Ph.D	35
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients	35
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	34
Neuropeptide Y in cancer—biological functions and potential clinical implications	33
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance	33
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	31
Biographies	31
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	30
Biographies	30
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance	29
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	27
Targeting DNA damage repair pathways in pancreas cancer	27
Clusterin: a marker and mediator of chemoresistance in colorectal cancer	26
Short-chain fatty acids in cancer pathogenesis	26
The role of cancer cell bioenergetics in dormancy and drug resistance	26
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy	25
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development	25
Tumor necrosis factor superfamily signaling: life and death in cancer	24
Vaping and tumor metastasis: current insights and progress	23
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology	23
Clinical interventions to break the obesity and cancer link: a narrative review	23
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions	23
Functional and clinical roles of stromal PDGF receptors in tumor biology	22
The emerging roles of histone demethylases in cancers	22
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy	22
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments	21
Carcinoma of unknown primary (CUP): an update for histopathologists	21
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions	21
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review	20
Debris-stimulated tumor growth: a Pandora’s box?	20
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	20
OX40/OX40 ligand and its role in precision immune oncology	20
Kenneth V. Honn, Ph.D. (1946–2023)	20
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape	20
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting	19
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy	19
HOXA9 transcription factor is a double-edged sword: from development to cancer progression	19
Inflammatory bowel disease and carcinogenesis	19
New progress of tuberculosis scar carcinoma	19
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance	18
Ferroptosis: iron release mechanisms in the bioenergetic process	18
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	18
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect	18
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective	17
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases	16
Is cancer an intelligent species?	16
Metastasis suppressor genes and their role in the tumor microenvironment	16
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics	16
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases	16
Biographies	16

Metastasis suppressor genes in clinical practice: are they druggable?	16
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs	16
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment	16
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX	16
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets	16
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy	15
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers	15
Oncobiology and treatment of breast cancer in young women	15
De- “bug”-ing the microbiome in lung cancer	15
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer	15
Lost at SCLC: a review of potential platinum sensitizers	15
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets	15
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer	14
The cure from within? a review of the microbiome and diet in melanoma	13
Glycosylation as a regulator of site-specific metastasis	13
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis	13
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma	13
Preface	12
The role of bone marrow adipocytes in cancer progression: the impact of obesity	12
Biography—Mikhail Kolonin	12
The diversity of natural killer cell functional and phenotypic states in cancer	12
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions	12
Preface	12
Role of myeloid-derived suppressor cells in tumor recurrence	12
The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues	11
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment	11
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine	11
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?	11
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer	11
The role of the metabolite cargo of extracellular vesicles in tumor progression	11
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors	11
Where is Waldo? or find the platelet	11
The role of obesity and bariatric surgery-induced weight loss in breast cancer	11
Biographies	11
Epigenetic control of pancreatic cancer metastasis	10
Epigenetic drugs in cancer therapy	10
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin	10
Potential biomarkers for immunotherapy in non-small-cell lung cancer	10
Nanotechnology-aided advancement in the combating of cancer metastasis	10
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives	10
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics	10
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance	10
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings	9
Correction to: Connecting the human microbiome and pancreatic cancer	9
Insights into the role of senescence in tumor dormancy: mechanisms and applications	9
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies	9
Models of pancreatic ductal adenocarcinoma	9
The timing of adiposity and changes in the life course on the risk of cancer	9
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response	9
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance	9
Epigenetic markers and therapeutic targets for metastasis	8
What do cellular responses to acidity tell us about cancer?	8
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases	8
Natural compounds targeting nuclear receptors for effective cancer therapy	8
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies	8
Advancements in gene therapies targeting mutant KRAS in cancers	8
Recapitulating the potential contribution of protein S-palmitoylation in cancer	8
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response	8
Preface	8
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance	8
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance	7
Evolving strategies for addressing CAR T-cell toxicities	7
The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas	6
Oral delivery of RNAi for cancer therapy	6
Retraction Note: EET signaling in cancer	6
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art	6
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma	6
Glioblastoma stem cell metabolism and immunity	6
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation	6
Regulation and targeting of SREBP-1 in hepatocellular carcinoma	6
Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer	6
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead	6
Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020	6